Cochlear FY26 slides: cash flow doubles despite margin pressure

In Cochlear Limited's fiscal year 2026 results announced on August 18, 2026, the Australian hearing implant maker reported a combined revenue of $2.3 billion, representing a 2% increase in constant currency, but underlying net profit fell 22% to $322 million. Despite pricing challenges, a fluctuating product mix, and manufacturing inefficiencies, strong cash flow more than doubled year-over-year, driven by the successful launch of its Nexa cochlear implant platform.

Shares rose 7.19% to $140.69 following positive investor reaction, though the stock remains below its 52-week high of $304.94. The company met the upper range of its revised guidance while advancing strategic priorities, focusing on the medicalization of adult hearing loss. Revenue from the cochlear implants segment, which accounts for 61% of total sales, remained flat in constant currency due to pricing pressure and shifts in geographic mix.

Developed markets showed slight growth, while Asia Pacific experienced 7% growth, supported by mature referral pathways in Australia and strong Nexa launch momentum in Korea.